RxSight Stock Still Seen with Upside After Revised Guidance Appears Conservative -- Market Talk

Dow Jones

2025/07/09

09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. "We believe the new guidance bakes in areas of conservatism," say the analysts. "Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months." They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden)

(END) Dow Jones Newswires

July 09, 2025 09:12 ET (13:12 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2550583146"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550583146\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550583146?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550583146","market":"nz","top_or_hot":-1,"title":"RxSight Stock Still Seen with Upside After Revised Guidance Appears Conservative -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. \"We believe the new guidance bakes in areas of conservatism,\" say the analysts. \"Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months.\" They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 09:12 ET (13:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight Stock Still Seen with Upside After Revised Guidance Appears Conservative -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight Stock Still Seen with Upside After Revised Guidance Appears Conservative -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-09 21:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. \"We believe the new guidance bakes in areas of conservatism,\" say the analysts. \"Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months.\" They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 09:12 ET (13:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXST","symbol_name":"RxSIGHT, INC.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550583146","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550583146","pubTimestamp":1752066720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. \"We believe the new guidance bakes in areas of conservatism,\" say the analysts. \"Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months.\" They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXST":"RxSIGHT, INC.","BK4539":"次新股","BK4198":"医疗保健用品"},"translate_title":"在修订后的指引显得保守后，RxSight股票仍有上涨空间——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXST":0.9},"content_text":"09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. \"We believe the new guidance bakes in areas of conservatism,\" say the analysts. \"Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months.\" They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 09:12 ET (13:12 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}